An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab; Erlotinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Roche
- 14 Mar 2018 Planned End Date changed from 25 Jan 2018 to 18 May 2018.
- 14 Mar 2018 Planned primary completion date changed from 25 Jan 2018 to 18 May 2018.
- 23 Nov 2017 Planned End Date changed from 22 Aug 2017 to 25 Jan 2018.